IJR News — today's news from every side

IJR News — today's news from every side

blockversewordysbillionaire.aiyourlistWhiteboardAppquizieunschool

Loading

Want your own hosted, self-optimizing clone of this — or any OpenServe site? Open Development for enterprise →

© OpenServe Holdings LLC

Privacy Notice Data rights Terms of Service Feedback Cookie NoticeHelp Acceptable Use Copyright AI Notice Your Privacy Choices Subprocessors Data Processing Addendum Installed App Terms Company Solutions Free assessment Investors Get the app Contact

News

Home
Politics
World
Sports
Markets
Business
Entertainment
Music
Health
Tech
Science
Good News
Encouragement
Video
Meme Wars

Brands

Yourlist
Quizie
FaithTap
Blessed
All brands

📊 Approval moversGordon Liu100%

Uvalde Shooter’s Grandma, 66, Triumphs Over Death After Being Shot, Instantly Reminds World What He Did to HerReporting — Jun 30, 2022For days, the world thought she was dead — the first of the many that would die on a May day that scarred the community of Uvalde, Texas, forever. But Celia Gonzales, the first person shot by her grandson Salvador Ramos…

Argenx plans $2.2B Forte Biosciences deal — Jul 27, 2026Argenx has agreed to acquire Forte Biosciences for about $2.2 billion in cash, offering $77 per Forte share and funded entirely from Argenx’s cash to complete a Q3 2026 closing after standard approvals and tender conditions. The deal adds Forte’s FB102, a first-in-class CD122 antibody for vitiligo and celiac disease with potential broader autoimmune applications, boosting Argenx's immunology pipeline beyond Vyvgart.

Ascelia Completes FDA Meeting on OrviglanceHealth — Sep 8, 2026Biopharma firms report a mix of regulatory progress: Ascelia Pharma advances its Orviglance NDA with an FDA Type A meeting held and minutes due in about 30 days, while AstraZeneca secures FDA approval for Etcamah (camizestrant) after an advisory panel opposed it earlier, signaling a potential shift in benefit-risk assessment. Ascletis Pharma launches a US Phase I trial for ASC36 obesity drug under an IND, highlighting ongoing development in metabolism therapies alongside expectations of further data and pricing implications for investors.